The company's product is a generic equivalent of Viatris Specialty LLC's Revatio, Lupin said in a statement. Drug maker Lupin on Thursday said it has launched Sildenafil for Oral Suspension, indicated for the treatment of pulmonary arterial hypertension, in the US market. The company said it has introduced the product after getting approval from the US Food and Drug Administration. The company's product is a generic equivalent of Viatris Specialty LLC's Revatio, Lupin said in a statement. According to IQVIA MAT July 2022 sales data, Sildenafil for Oral Suspension had estimated annual sales of USD 64 million in the US. Shares of Lupin on Thursday closed 2.46 per cent down at Rs 654.00 apiece on the BSE
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!